Vaccines under development: Helicobacter pylori;Vacunas en desarrollo: Helicobacter pylori

Revista Chilena de Infectologia

Volumn 23, Issue 3, 2006, Pages 249-256

  Harris D , Paul ^a   Serrano H , Carolina ^a   Venegas E , Alejandro ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Facultad de Ciencias Biologicas   (Chile)

Author keywords

Gastric cancer prevention; Helicobacter pylori; Vaccine

Indexed keywords

BACTERIAL VACCINE;

ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; MOUSE; REVIEW;

ANIMALS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 33748993727     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Rollán A, Ferreccio C, Harris P, Serrano C, Jara A, Venegas A. Early Helicobacter pylori infection is related to gastric cancer risk in Chile, a high-risk area: A population-based study. Can J Gastroenterol 2005; 19-43.
2. Nomura A, Stemmermann G N, Chyou P H, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132-6.
3. Parsonnet J, Blaser M J, Pérez-Pérez G I, et al. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologist. Gastroenterol 1992; 102: 41-6.
4. Forman D, Newell D G, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. Br Med J 1991; 302: 1302-5.
5. Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996; 9: 246-57.
6. Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004; 64: 1893-904.
7. Ford A C, Delaney B C, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99: 1833-55.
8. Kusters J G. Recent developments in Helicobacter pylori vaccination. Scan J Gastroenterol 2001; 36 Suppl 234: 15-21.
9. Lee A, Fox J G, Otto G, Murphy J A. Small animal model of human and Helicobacter pylori active chronic gastritis. Gastroenterol 1999; 99: 1315-23.
10. Czinn S J, Nedrud J G. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 1993; 11: 637-42.
11. Cellini L, Allocati N, Angelucci D, Iezzi T, Di Campli E, Marzio L, et al. Coccoid Helicobacter pylori not culturable in vitro reverts in mice. Microbiol Immunol 1994; 38: 843-50.
12. Marchetti M, Arico B, Burroni D, Figura N, Rappuoli R, Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995; 267: 1655-8.
13. Lee A, O'Rourke J, De Ungria M C, Robertson B, Daskalopoulos G, Dixon M F. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterol 1997; 112: 1386-97.
14. Garhart C A, Redline R W, Nedrud J G, Czin SJ. Clearance of Helicobacter pylori infection and resolution of post-immunization gastritis in a kinetic study of prophylactically immunized mice. Infect Immun 2002; 70: 3529-38.
15. Garhart C A, Heinzel F P, Czin S J, Nedrud J G. Vaccine induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect Immun 2003; 71: 910-21.
16. Shi T, Liu W Z, Gao F, Shi G Y, Xiao S D. Intranasal CpG- oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper I type response and IFN-γ correlate with the protection. Helicobacter 2005; 10: 71-9.
17. Sommer F, Wilken H, Faller G, Lohoff M. Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG-oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. Infect Immun 2004; 72: 1029-35.
18. Rahn W, Redline R W, Blanchard T G. Molecular analysis of Helicobacter pylori-associated gastric inflammation in naïve versus previously immunized mice. Vaccine 2004; 23: 807-18.
19. Garhart C A, Nedrud J G, Heinzel F P, Sigmund N E, Czin S J. Vaccine induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin-4. Infect Immun 2003; 71: 3628-33.
20. Panthel K, Faller G, Haas R. Colonization of C57BL/6J and BALB/c wild-type and knockout mice with Helicobacter pylori: Effect of vaccination and implications for innate and acquired immunity. Infect Immun 2003; 71: 794-800.
21. Kim J S, Chang J H, Chung S, Yum J S. Importance of host genetic background on immune response to Helicobacter pylori infection and therapeutic vaccine efficacy. FEMS Immun Med Microbiol 2001; 31: 41-6.
22. Raghavan S, Svennerholm A M, Homgren J. Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. Infect Immun 2002; 70: 4621-7.
23. Raghavan S, Hjustrom M, Homgren J Svennerholm A M. Protection against experimental Helicobacter pylori immunization with inactivated H. pylori whole-cell vaccines. Infect Immun 2002; 70: 6383-8.
24. Koesling J, Lucas B, Develioglou L, Aebischer T, Meyer T F. Vaccination of mice with live recombinant Salmonella typhimurium aroA against H. pylori: parameters associated with prophylactic and therapeutic vaccine efficacy. Vaccine 2001; 20: 413-20.
25. Londoño-Arcila P, Freeman D, Kleathous H, O'Dowd A M, Lewis S, Turner AK, et al. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunized mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun 2002; 70: 5096-106.
26. Todoroki I, Joh T, Watanabe K, Miyashita M, Seno K, Nomura T, et al. Suppressive effects of DNA vaccines encoding heat shock proteins on Helicobacter pylori-induced gastritis in mice. Biochem Biophys Res Commun 2000; 277: 159-63.
27. Miyashita M, Joh T, Watanabe K, Todoroki I, Seno K, Ohara H, et al. Immune response in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori-catalase. Vaccine 2002; 20: 2336-42.
28. Smythies L E, Novak M J, Waites K B, Lindsey J R, Morrow C D, Smith P D. Poliovirus replicons encoding the B subunits of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 2005; 23: 901-9.
29. Kotloff K L, Sztein M B, Wasserman S S, Losonsky G A, DiLorenzo S C, Walker R I. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001; 69: 3581-90.
30. Losonsky G, Kotloff K, Walker R. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT R192G in H. pylori seronegative individuals. Vaccine 2003; 21: 562-5.
31. Kreiss C, Buclin T, Cosma M, Corthesy-Theulaz I, Michetti P. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet 1996; 347: 1630-1.
32. Michetti P, Kreiss C, Kotloff K, et al. Oral immunization with urease and E. coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterol 1999; 116: 804-12.
33. Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J, et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002; 51: 634-40.
34. Sougioultzis S, Lee C K, Alsahli M, Banerjee S, Cadoz M, Schrader R, et al. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002; 21: 194-201.
35. DiPetrillo M D, Tibbetts T, Kleanthous H, Killeen K, Hohmann E L. Safety and immunogenicity of phoO/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999; 18: 449-59.
36. Angelakopoulos H, Hohmann E L. Pilot study of phoO/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000; 68: 2135-41.
37. Bumann D, Metzger W, Mansouri E, Palme O, Wendland M, Hurwitz R, et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001; 20: 854-52.
38. Metzger W, Mansouri E, Kronawitter M, Diescher S, Soerensen M, Hurwitz R, et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar Typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004; 22: 2273-7.
39. Malfertheiner P, Schultze V, Del Giudice G, Rosenkranz B, Kaufmann S H E, Winau F, et al. Phase I safety and immunogenicity of a three-component H. pylori vaccine. Gastroenterol 2002, S 122, A-585.
40. Ruggiero P, Peppoloni S, Rappuoli R, Del Giudice G. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microbes Infect 2003; 5: 749-56.
41. Johansson E L, Bergquist C, Edebo A, Johansson C, Svennerholm A M. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 2004; 22: 984-90.
42. Bumann D, Jungblut P, Meyer T. Helicobacter pylori vaccine development based on combined subproteome analysis. Proteomics 2004; 4: 2843-8.
43. Michetti P. Experimental Helicobacter pylori infection in humans: a multifaceted challenge. Gut 2004; 53: 1220-1.
44. Graham D Y, Opekun A R, Osato M S, El-Zimaity H M, Lee CL, Yamaoka Y, et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004; 53: 1235-43.